Kairos Pharma’s (KAPA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $9.00 price objective on the stock.

Kairos Pharma Stock Up 2.5 %

Shares of NYSEAMERICAN:KAPA opened at $1.63 on Wednesday. Kairos Pharma has a 1-year low of $0.85 and a 1-year high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.